Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meplazumab in Patients With COVID-19
NCT05113784Phase 3Completed
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Meplazumab Arm with Placebo Arm (2 arms). Primary endpoint: Time of virus nucleic acid test turning negative up to 14 days. Started Jan 2022; status: completed.
02
Drugs
meplazumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05113784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113784.